

# Chiara Rosso

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/726627/publications.pdf>

Version: 2024-02-01

88  
papers

3,916  
citations

159585

30  
h-index

133252

59  
g-index

88  
all docs

88  
docs citations

88  
times ranked

5783  
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. <i>Annual Review of Medicine</i> , 2016, 67, 103-117.	12.2	535
2	Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance. <i>Hepatology</i> , 2018, 67, 145-158.	7.3	296
3	Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. <i>Hepatology</i> , 2020, 71, 1213-1227.	7.3	209
4	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	205
5	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. <i>Scientific Reports</i> , 2017, 7, 4492.	3.3	193
6	Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers. <i>International Journal of Molecular Sciences</i> , 2016, 17, 717.	4.1	158
7	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	3.7	149
8	Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 71, 1012-1021.	3.7	128
9	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. <i>Gut</i> , 2022, 71, 382-390.	12.1	113
10	Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2014, 9, e87523.	2.5	112
11	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 786-794.	3.7	100
12	The macrophage activation marker $\alpha$ CD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2016, 36, 1549-1557.	3.9	94
13	Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load. <i>International Journal of Molecular Sciences</i> , 2016, 17, 479.	4.1	70
14	Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2016, 63, 107-116.	7.3	67
15	Hypoxia-inducible factor 2 $\alpha$ drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine-rich glycoprotein. <i>Hepatology</i> , 2018, 67, 2196-2214.	7.3	66
16	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2310-2319.e6.	4.4	66
17	Serum zonulin in patients with inflammatory bowel disease: a pilot study. <i>Minerva Medica</i> , 2019, 110, 95-100.	0.9	66
18	Physiopathology of intestinal barrier and the role of zonulin. <i>Minerva Biotechnologica</i> , 2019, 31, .	1.2	66

#	ARTICLE	IF	CITATIONS
19	Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0163069.	2.5	63
20	Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with nonalcoholic steatohepatitis and advanced fibrosis. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1202-1208.	2.8	55
21	Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. Scandinavian Journal of Gastroenterology, 2014, 49, 1419-1424.	1.5	54
22	Liver fibrosis: the 2017 state of art. Panminerva Medica, 2017, 59, 320-331.	0.8	53
23	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. Liver International, 2017, 37, 1389-1396.	3.9	44
24	Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. Metabolites, 2021, 11, 155.	2.9	44
25	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Cancer Medicine, 2017, 6, 1930-1940.	2.8	43
26	Fecal calprotectin: beyond intestinal organic diseases. Panminerva Medica, 2018, 60, 29-34.	0.8	41
27	Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2017, 112, 1277-1286.	0.4	38
28	Rare ATG7 genetic variants predispose patients to severe fatty liver disease. Journal of Hepatology, 2022, 77, 596-606.	3.7	38
29	How to diagnose NAFLD in 2016. Journal of Hepatology, 2016, 65, 643-644.	3.7	36
30	Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II. Panminerva Medica, 2017, 59, 283-289.	0.8	35
31	Molecular mechanisms of hepatic fibrosis in chronic liver diseases. Minerva Biotechnologica, 2020, 32, .	1.2	33
32	Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation. Digestive and Liver Disease, 2019, 51, 1400-1408.	0.9	31
33	Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2013, 11, 311-317.e1.	4.4	30
34	On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2020, 9, 800.	2.4	29
35	Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. Cancers, 2020, 12, 3218.	3.7	27
36	The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review. Frontiers in Endocrinology, 2021, 12, 716533.	3.5	27

#	ARTICLE	IF	CITATIONS
37	Oncostatin M, A Profibrogenic Mediator Overexpressed in Non-Alcoholic Fatty Liver Disease, Stimulates Migration of Hepatic Myofibroblasts. <i>Cells</i> , 2020, 9, 28.	4.1	26
38	Altered Metabolic Profile and Adipocyte Insulin Resistance Mark Severe Liver Fibrosis in Patients with Chronic Liver Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6333.	4.1	24
39	Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 2305.	3.7	24
40	Usefulness of the index of <sc>NASH</sc> â€“ <sc>ION</sc> for the diagnosis of steatohepatitis in patients with nonâ€œalcoholic fatty liver: An external validation study. <i>Liver International</i> , 2018, 38, 715-723.	3.9	22
41	Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8838.	4.1	22
42	Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. <i>Minerva Medica</i> , 2019, 110, 401-409.	0.9	22
43	Hepatitis B coreâ€related antigen kinetics in chronic hepatitis B virus genotype Dâ€infected patients treated with nucleos(t)ide analogues or pegylatedâ€interferonâ€±. <i>Hepatology Research</i> , 2017, 47, 747-754.	3.4	20
44	<i>IL28B</i> polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 13146.	3.3	20
45	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. <i>JHEP Reports</i> , 2022, 4, 100409.	4.9	20
46	Chronic hepatitis <sc>C</sc> virus infection and lymphoproliferative disorders: Mixed cryoglobulinemia syndrome, monoclonal gammopathy of undetermined significance, and <sc>B</sc>â€cell nonâ€<sc>H</sc>odgkin lymphoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 742-747.	2.8	19
47	Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. <i>Digestive and Liver Disease</i> , 2016, 48, 55-61.	0.9	19
48	Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report. <i>Journal of Clinical Medicine</i> , 2020, 9, 2353.	2.4	18
49	Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic Acid Breath Test. <i>Minerva Medica</i> , 2017, 108, 489-495.	0.9	17
50	Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohnâ€™s Disease: A Prospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3387.	2.4	16
51	The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease. <i>Journal of Advanced Research</i> , 2021, 33, 183-187.	9.5	16
52	Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2776.	3.7	14
53	Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114985.	1.8	14
54	Laboratory evidence of Helicobacter species infection in hepatocellular carcinoma. <i>Minerva Biotecnologica</i> , 2018, 30, .	1.2	13

#	ARTICLE	IF	CITATIONS
55	Hepatocyte-Specific Deletion of HIF2 $\alpha$ Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 459-482.	4.5	13
56	Non-invasive methods for the assessment of hepatic fibrosis: transient elastography, hyaluronic acid, 13C-aminopyrine breath test and cytokeratin 18 fragment. <i>Annals of Hepatology</i> , 2014, 13, 91-97.	1.5	12
57	Diagnosis of <i>Helicobacter pylori</i> infection: a look into molecular aspects of urea breath test. <i>Minerva Biotecnologica</i> , 2019, 31, .	1.2	12
58	Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 635.	2.4	12
59	Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis. <i>Journal of Pathology</i> , 2022, 257, 82-95.	4.5	12
60	Occult Hepatitis B Virus Infection in Patients With Chronic Hepatitis C Treated With Antiviral Therapy. <i>Hepatitis Monthly</i> , 2012, 12, e7292.	0.2	9
61	Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 1289-1292.	0.4	9
62	Mechanisms for increased risk of diabetes in chronic liver diseases. <i>Liver International</i> , 2020, 40, 2489-2499.	3.9	9
63	Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis. <i>Diagnostics</i> , 2021, 11, 187.	2.6	9
64	Inflammatory Bowel Disease Nurseâ€™ Practical Messages. <i>Nursing Reports</i> , 2021, 11, 229-241.	2.1	8
65	Efficacy of a Preparation Based on Calcium Butyrate, <i>Bifidobacterium bifidum</i> , <i>Bifidobacterium lactis</i> , and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4961.	2.4	8
66	Non-invasive markers to detect colorectal cancer in asymptomatic population. <i>Minerva Biotecnologica</i> , 2019, 31, .	1.2	6
67	Basic and clinical aspects of resistin. <i>Minerva Biotecnologica</i> , 2018, 30, .	1.2	5
68	Circulating Zonulin is Related to Hepatic Necroinflammation in Patients with Non Alcoholic Fatty Liver Disease. <i>Clinical Laboratory</i> , 2020, 66, .	0.5	5
69	The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. <i>Biology</i> , 2021, 10, 215.	2.8	4
70	Moving towards core antigen for the management of patients with overt and occult HBV infection. <i>Panminerva Medica</i> , 2020, , .	0.8	4
71	Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification. <i>Biomedicines</i> , 2022, 10, 792.	3.2	4
72	Performance of cytokeratin-18 apoptotic fragment for the identification of hepatic fibrosis and inflammation in patients with chronic viral hepatitis: a meta-analysis. <i>Minerva Biotecnologica</i> , 2021, 32, .	1.2	3

#	ARTICLE	IF	CITATIONS
73	Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2020, 7, 616212.	2.6	2
74	Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 3257.	2.4	2
75	Usefulness of fecal calprotectin determination in pediatric intestinal diseases. <i>Minerva Pediatrica</i> , 2016, 68, 478-486.	2.7	2
76	PS-205-Longitudinal prognostic value of the most common algorithms for fibrosis in non-alcoholic fatty liver disease: An international study in non-cirrhotic, biopsy-proven patients. <i>Journal of Hepatology</i> , 2019, 70, e136-e137.	3.7	1
77	THU-208-Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA. <i>Journal of Hepatology</i> , 2019, 70, e254-e255.	3.7	1
78	A Retrospective Experience of Helicobacter pylori Histology in a Large Sample of Subjects in Northern Italy. <i>Life</i> , 2021, 11, 650.	2.4	1
79	Considerations on meta-analyses regarding the association between long non-coding RNA and neoplasms. <i>Minerva Medica</i> , 2017, 109, 68.	0.9	1
80	Role of miR-503 in gastric cancer. <i>Panminerva Medica</i> , 2018, 60, 227-228.	0.8	1
81	Non-invasive methods for the assessment of hepatic fibrosis: transient elastography, hyaluronic acid, 13C-aminopyrine breath test and cytokeratin 18 fragment. <i>Annals of Hepatology</i> , 2013, 13, 91-7.	1.5	1
82	THU-464-NASH-related liver carcinogenesis is critically affected by hypoxia-inducible factor 2 alpha. <i>Journal of Hepatology</i> , 2019, 70, e363-e364.	3.7	0
83	Analytical and clinical comparison between two different chemiluminescent enzyme immunoassays for the measurement of C-peptide in serum. <i>Minerva Biotechnology and Biomolecular Research</i> , 2021, 33, .	0.5	0
84	Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101611.	1.5	0
85	Role of triglycerides to high-density lipoprotein cholesterol ratio in non-alcoholic fatty liver disease progression. <i>Minerva Gastroenterology</i> , 2021, , .	0.5	0
86	Is the pattern of liver disease etiology changing in China?. <i>Minerva Medica</i> , 2021, 112, 521.	0.9	0
87	Chronic Hepatitis B Treatment: Current Perspectives on Telbivudine. <i>Ä°stanbul Medical Journal</i> , 2017, 18, 189-195.	0.1	0
88	A Comment on the Letter. <i>Archives of Iranian Medicine</i> , 2016, 19, 886.	0.6	0